REG - Ergomed plc - Ergomed Award of Share Options to Director <Origin Href="QuoteRef">ERGO.L</Origin>

ErgomedAnnouncement

11/01/2016 07:11

RNS Number : 3622L
Ergomed plc
11 January 2016
Ergomed Award of Share Options to Director
Guildford, UK - 11 January 2016: Ergomed plc, (LSE: ERGO or 'Ergomed') a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces that the following LTIP (Long Term Investment Plan) award has been made under its Unapproved Executive Share Option Scheme to Stephen Stamp the newly appointed director of the Company.
The award consists of 400,000 share options over the Company's ordinary shares having a nominal value of 1 pence each (the "Options") with an exercise price of 1 pence per share. 200,000 of the Options will vest after three years and are not subject to performance criteria. The remaining 200,000 will vest based on total shareholder return ("TSR") over the three year vesting period with a minimum and maximum of 10 per cent. and 25 per cent. per annum respectively. If TSR over the vesting period is between the minimum and maximum, the performance options vest proportionately. 
Once vested the options will be exercisable until 11 January 2026.
Director
Award of Options
Resulting interest in options
Current shareholding in the Company
Stephen Stamp - Chief Financial Officer
400,000
400,000
NIL
In total 400,000 Options were granted yesterday, representing 1.4 per cent. of the issued share capital.
For further information, please contact:
Hume Brophy - for UK enquiries
Mary Clark, Supriya Mathur and Hollie Vile
Tel: + 44 203 440 5654
ergomed@humebrophy.com
Stifel 
NOMAD/Broker to the Company
Jonathan Senior, Stewart Wallace and Ben Maddison
Tel: +44 207 710 7600
MC Services - for Continental European enquiries
Anne Hennecke
Tel: +49 211 529252 22
anne.hennecke@mc-services.eu
About Ergomed plc
Founded in 1997, Ergomed plc is a profitable UK-based company, providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 40 countries.
Ergomed provides clinical development, trial management and pharmacovigilance services to over 60 clients ranging from top 10 pharmaceutical and generics companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.
Ergomed has wide therapeutic expertise, with a particular focus in oncology, neurology and immunology and the development of orphan drugs. Ergomed'sapproach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies. Here Ergomed shares the risks and rewards of drug development, leveraging its expertise and services in return for carried interest in the drugs under development. - a low risk investment model for potential high returns. For further information, visit: http://ergomedplc.com.
Global pharmacovigilance and medical information services are provided through its group company PrimeVigilance. www.primevigilance.com

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCSSLFWAFMSEFF